secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2026-10-08T13:24:36+00:00
Accession:  0001104659-26-114571
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Viatris to acquire Pacira BioSciences for $36.50/share cash, $1.65B equity value
--------------------------------------------------------------------------------

- Viatris agreed to acquire Pacira for $36.50/share in cash, aggregate equity value $1.65B; tender offer to commence within 15 business days.
- Pacira generated approximately $746M total revenue and approximately $177M adjusted EBITDA for the last twelve months ended June 30, 2026.
- Deal adds EXPAREL (bupivacaine liposome) and ZILRETTA (triamcinolone acetonide) non-opioid pain products; expected close by end of 2026.
- Viatris expects immediate accretion to guidance metrics; funded primarily from excess cash with remainder short-term borrowings; minimal impact on gross leverage ratio.
- Pacira would pay $62.0M termination fee if it accepts a superior offer; merger under Delaware Section 251(h), no shareholder vote required.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000110465926114571/0001104659-26-114571-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000110465926114571/tm2627240d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-114571

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer